Anti-Depression API Escitalopram Oxalate Powder Pharmaceutical Escitalopram Oxalate

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-Escitalopram Oxalate
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Escitalopram Oxalate
• Name: Escitalopram Oxalate Powder
• Appearance: White Powder
• Colour: White
• Grade: Pharmaceutical Grade
• Assay: >99%
• Application: API
• Specific: COA
• Test Method: HPLC
• Mf: C22h23fn2o5
• MW: 414.433
• CAS: 219861-08-2
• Melting Point: 152-153 C
• Boiling Point: 428.3c
• Psa: 110.86000
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS-Escitalopram Oxalate
• Origin: Xian
• Production Capacity: 100kg/Month

Product Description

Anti-Depression API Escitalopram Oxalate Powder Pharmaceutical Escitalopram Oxalate

Product Description

Product Details

Product Name	Escitalopram Oxalate
Appearance	Escitalopram Oxalate Powder
Assay	99%
MW	414.433
MF	C22H23FN2O5

Escitalopram oxalate is a selective serotonin reuptake inhibitor. It is suitable for the treatment of depression, especially severe depression and generalized anxiety disorder. It has good clinical efficacy, less adverse reactions and good compliance.

Application&Function

1.It has no obvious reaction to cardiovascular system, and has strong antidepressant effect.
2.It is suitable for patients with somatic diseases accompanied with depression and need multiple drugs. At the same time, escitalopram oxalate can also inhibit platelet aggregation, protect endothelial function, reduce inflammatory reaction, thus preventing the occurrence and development of atherosclerosis and stabilizing plaque;
3.in addition, it can effectively stabilize myocardial oxygen consumption, thus improving coronary blood supply and reducing coronary symptoms.

4. Erlotinib hydrochloride is a kind of small molecule epidermal receptor tyrosine kinase reversible inhibitor. It is mainly used for the second-line or third-line treatment of locally advanced or metastatic non-small cell lung cancer and for the treatment of pancreatic cancer.

5. HER-1/EGFR tyrosine kinase inhibitors.

Specification